EQS-News CureVac Welcomes Myriam Mendila as New Chief Development Officer
Issuer: CureVac / Key word(s): Personnel
CureVac Welcomes Myriam Mendila as New Chief Development Officer
- Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced.
“Myriam’s extensive expertise in product development in the global pharmaceutical industry, particularly the past several years in oncology, will be a significant asset to CureVac as we continue to advance our mRNA product pipeline. On behalf of the entire team, I would like to offer Myriam a very warm welcome as a new member of CureVac’s management,” said Franz-Werner Haas, Chief Executive Offer at CureVac. “I would also like to extend my wholehearted thanks to Ulrike Gnad-Vogt for stepping in as Interim Chief Development Officer during the past eight months.”
“I’m truly excited to join CureVac at this important inflection point of the company,” said Dr. Mendila. “The latest data update from the COVID-19 and flu programs demonstrates the potential of CureVac’s broad technology platform to help fighting the most pressing health challenges and supports its competitive position as a key player in the mRNA field. I’m looking forward to working with the CureVac team to build on these data, not only in infectious diseases but across CureVac’s therapeutic areas.”
Myriam Mendila, MD, has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including commercial strategy at Roche, Genentech and Novartis. Over the last 5 years, she has held the position of Chief Medical Officer Oncology and Global Head of Oncology Medical Affairs at Novartis, being responsible for the Medical Affairs strategy and related activities across the overall oncology portfolio at Novartis. Myriam earned her medical degree and subsequently doctoral degree from the Medical University of Hannover, Germany.
|Diskussion: CureVac ist endlich an der Börse|